1645

TKW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: R. S. Tedder *et al.*

Serial No.: 09/402,282

Filed: April 25, 1997

For: HEPATITIS MONOCLONAL ANTIBODIES

Attorney Docket No.: 6508.US.O1

Date: August 12, 2005

Examiner: P.A. Duffy

Group Art Unit: 1645

Certificate of Mailing under 37 CFR §1.8(a):
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Kim Annel 8/12/05
Name: Kim Annel Date

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith for the patent application identified above entitled HEPATITIS MONOCLONAL ANTIBODIES are the following:

1. Statement Under 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d) – 1pg.;
2. Amendment – 3 pgs.;
3. Sequence Listing – 3 pgs.;
4. Computer Readable Format of Sequence Listing – 1 diskette; and
5. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted,
R.S. Tedder *et al.*

Dianne Casuto

ABBOTT LABORATORIES
D-377/AP6A-1
100 Abbott Park Road
Abbott Park, IL 60064-3500
Telephone: (847) 938-3137
Facsimile: (847) 938-2623

Dianne Casuto
Registration No. 40,943
Attorney for Applicants

NOTICE TO COMPLY	Application/Control No.	Applicant(s)	
	09/402,282	TEDDER ET AL.	
	Examiner	Art Unit	
	Laurie A. Scheiner	1648	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e)

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☐ 7. Other: .

Applicant Must Provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include n new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510
For CRF Submission Help, call (571) 272-2501/2583.
PatentIn Software Program Support
Technical Assistance.....703-287-0200
To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY